SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Ruggeri A) "

Sökning: WFRF:(Ruggeri A)

  • Resultat 21-30 av 72
  • Föregående 12[3]4567...8Nästa
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
21.
  •  
22.
  • Bernal, Ximena E., et al. (författare)
  • Empowering Latina scientists
  • 2019
  • Ingår i: Science. - 0036-8075. ; 363:6429, s. 825-826
  • Tidskriftsartikel (övrigt vetenskapligt)
  •  
23.
  •  
24.
  • De Stefano, V., et al. (författare)
  • High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with Vitamin K antagonists
  • 2016
  • Ingår i: Leukemia. - : Nature Publishing Group. - 0887-6924. ; 30:10, s. 2032-2038
  • Tidskriftsartikel (refereegranskat)abstract
    • The optimal duration of treatment with vitamin K antagonists (VKA) after venous thromboembolism (VTE) in patients with Philadelphia-negative myeloproliferative neoplasms (MPNs) is uncertain. To tackle this issue, we retrospectively studied 206 patients with MPN-related VTE (deep venous thrombosis of the legs and/or pulmonary embolism). After this index event, we recorded over 695 pt-years 45 recurrences, venous in 36 cases, with an incidence rate (IR) of 6.5 per 100 pt-years (95% confidence interval (CI): 4.9-8.6). One hundred fifty-five patients received VKA; the IR of recurrent thrombosis per 100 pt-years was 4.7 (95% CI: 2.8-7.3) on VKA and 8.9 (95% CI: 5.7-13.2) off VKA (P=0.03). In patients receiving VKA, the IR of recurrent thrombosis per 100 pt-years was 5.3 (95% CI: 3.2-8.4) among 108 patients on long-term VKA and 12.8 (95% CI: 7.3-20.7) after discontinuation among the 47 who ceased treatment (P=0.008), with a doubled risk of recurrence after stopping VKA (hazard ratio: 2.21, 95% CI: 1.19-5.30). The IR of major bleeding per 100 pt-years was 2.4 (95%: CI: 1.1-4.5) on VKA and 0.7 (95% CI: 0.08-2.5) off VKA (P=0.08). In conclusion, in MPN patients with VTE recurrent thrombosis is significantly reduced by VKA and caution should be adopted in discontinuation; however, the incidence of recurrence on treatment remains high, calling for clinical trials aimed to improve prophylaxis in this setting.
  •  
25.
  • De Stefano, V., et al. (författare)
  • Splanchnic vein thrombosis in myeloproliferative neoplasms : Risk factors for recurrences in a cohort of 181 patients
  • 2016
  • Ingår i: Blood Cancer Journal. - : Nature Publishing Group. - 2044-5385. ; 6:11
  • Tidskriftsartikel (refereegranskat)abstract
    • We retrospectively studied 181 patients with polycythaemia vera (n=67), essential thrombocythaemia (n=67) or primary myelofibrosis (n=47), who presented a first episode of splanchnic vein thrombosis (SVT). Budd-Chiari syndrome (BCS) and portal vein thrombosis were diagnosed in 31 (17.1%) and 109 (60.3%) patients, respectively; isolated thrombosis of the mesenteric or splenic veins was detected in 18 and 23 cases, respectively. After this index event, the patients were followed for 735 patient years (pt-years) and experienced 31 recurrences corresponding to an incidence rate of 4.2 per 100 pt-years. Factors associated with a significantly higher risk of recurrence were BCS (hazard ratio (HR): 3.03), history of previous thrombosis (HR: 3.62), splenomegaly (HR: 2.66) and leukocytosis (HR: 2.8). Vitamin K-antagonists (VKA) were prescribed in 85% of patients and the recurrence rate was 3.9 per 100 pt-years, whereas in the small fraction (15%) not receiving VKA more recurrences (7.2 per 100 pt-years) were reported. Intracranial and extracranial major bleeding was recorded mainly in patients on VKA and the corresponding rate was 2.0 per 100 pt-years. In conclusion, despite anticoagulation treatment, the recurrence rate after SVT in myeloproliferative neoplasms is high and suggests the exploration of new avenues of secondary prophylaxis with new antithrombotic drugs and JAK-2 inhibitors.
  •  
26.
  •  
27.
  •  
28.
  •  
29.
  •  
30.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 21-30 av 72
  • Föregående 12[3]4567...8Nästa
Typ av publikation
tidskriftsartikel (60)
konferensbidrag (9)
forskningsöversikt (2)
rapport (1)
Typ av innehåll
refereegranskat (58)
övrigt vetenskapligt (14)
Författare/redaktör
Gabrielli, A. (13)
Rinaldi, L. (13)
Santi, L. (13)
Mecocci, P (13)
Perri, L. (13)
Clerici, M (13)
visa fler...
Damiani, G (13)
Vannini, G (13)
Loparco, F. (13)
Galanti, G. (13)
Ballestrero, A. (13)
Vigorito, C. (13)
Zanetti, M. (13)
Cittadini, A. (13)
Domínguez, L (13)
Leonardi, R. (13)
Vignali, A (13)
Girelli, D (13)
Brucato, A (13)
del Giacco, S (13)
Cattaneo, M (13)
Zoli, M (13)
Agosti, P (13)
Vella, FS (13)
Suppressa, P (13)
Nobili, A (13)
Mannucci, PM (13)
Sabba, C (13)
Prisco, D (13)
Silvestri, E (13)
Emmi, G (13)
Biolo, G (13)
Guadagni, M (13)
Zaccari, M (13)
Vanoli, M (13)
Grignani, G (13)
Pulixi, EA (13)
Bernardi, M (13)
Zaccherini, G (13)
Lupattelli, G (13)
Mannarino, E (13)
Bianconi, V (13)
Paciullo, F (13)
Nuti, R (13)
Valenti, R (13)
Ruvio, M (13)
Cappelli, S (13)
Palazzuoli, A (13)
Barbagallo, M (13)
Cocita, F (13)
visa färre...
Lärosäte
Karolinska Institutet (53)
Uppsala universitet (8)
Lunds universitet (8)
Umeå universitet (3)
Linköpings universitet (2)
Göteborgs universitet (1)
visa fler...
Kungliga Tekniska Högskolan (1)
Stockholms universitet (1)
Chalmers tekniska högskola (1)
visa färre...
Språk
Engelska (72)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (14)
Naturvetenskap (5)
Samhällsvetenskap (3)
Teknik (1)
Lantbruksvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy